ライフサイエンスコーパス: adjunctive therapy

1 AgNPs are a reasonable alternative to MMC as adjunctive therapy.

2 temic compartments are needed for effective, adjunctive therapy.

3 n coagulation (IAC), is now commonly used as adjunctive therapy.

4 (VNS) is licensed in several countries as an adjunctive therapy.

5 stered antifungal agent, may be an effective adjunctive therapy.

6 medical therapy and thus might be useful as adjunctive therapy.

7 Transsphenoidal adenomectomy and as-needed adjunctive therapy.

8 often given as monotherapy as well as early adjunctive therapy.

9 , baclofen and other medications are used as adjunctive therapy.

10 part of the aim of all chemical anti-plaque adjunctive therapy.

11 atients (33%) continued OAT after LAAO as an adjunctive therapy.

12 livery of bone morphogenetic protein-2 as an adjunctive therapy.

13 mation would yield potential new targets for adjunctive therapy.

14 ole for MIF as a target of immune-modulating adjunctive therapy.

15 nti-CPS mAbs encourages their development as adjunctive therapy.

16 on of VT is currently recommended only as an adjunctive therapy.

17 have stimulated research efforts to develop adjunctive therapies.

18 tification of new clinical interventions and adjunctive therapies.

19 med at using virulence factor antagonists as adjunctive therapies.

20 ), provides a range of molecular targets for adjunctive therapies.

21 ncluding ease of dosing and combination with adjunctive therapies.

22 ortant advances in intravenous nutrition and adjunctive therapies.

23 ysiology as well as the influence of age and adjunctive therapies.

24 onse impedes the development of vaccines and adjunctive therapies.

25 trains and help optimize dosing frequency or adjunctive therapies.

26 blockers can abrogate such entry, suggesting adjunctive therapies.

27 a lower Pa o2 :F io2 (P/F) and higher use of adjunctive therapies.

28 rther enhancements in clinical outcomes, and adjunctive therapies.

29 mpairments in patients with schizophrenia as adjunctive therapies.

30 r severe or complicated CDI, with or without adjunctive therapies.

31 mportant implications for the development of adjunctive therapies.

32 lity is high and so attention has focused on adjunctive therapies; adjunctive corticosteroids are ben

33 The correct adjunctive therapy administered along with reperfusion h

34 eding and suggest it is a safe and effective adjunctive therapy after variceal obliteration technique

35 Consequently, different adjunctive therapies aimed at modulating malaria pathoph

36 This intervention could prove useful as an adjunctive therapy aimed at reducing mortality rates in

37 myocardial infarct size by administration of adjunctive therapies along with reperfusion therapy.

38 Is laser therapy, as a monotherapy or as an adjunctive therapy, an efficacious treatment modality fo

39 nal physical or psychological evidence-based adjunctive therapies and combined therapies that can be

40 y and inform the design of disease-modifying adjunctive therapies and next-generation malaria vaccine

41 l data are needed on selection and dosing of adjunctive therapies and on complications in the elderly

42 spontaneously cleared the infection without adjunctive therapy and demonstrated higher levels of Th2

43 Novel trial designs, such as time-to-event adjunctive therapy and historical-control monotherapy, m

44 bone penetration, and the use of rifampin as adjunctive therapy), and the role of biomarkers and imag

45 us open surgical treatment, regenerative and adjunctive therapies, and other important aspects of CLI

46 ferences may reflect differing trial design, adjunctive therapies, and/or limited power.

47 episodes among those with recurrences, less adjunctive therapy, and an acceptable side-effect profil

48 event, clinical consequences, risk factors, adjunctive therapy, and new preventive approaches.

49 recautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation.

50 to develop toxin-neutralizing antibodies as adjunctive therapies are justified, given the high morta

51 for treating R. equi pneumonia in foals, and adjunctive therapies are needed.

52 ion, newer treatments that are used as early adjunctive therapy are dorzolamide, brinzolamide, apracl

53 Novel approaches for adjunctive therapy are urgently needed for complicated i

54 and therefore represents a prime target for adjunctive therapy based on small-molecule kinase inhibi

55 ted a possible role for anti-TNF antibody as adjunctive therapy, but this possibility requires confir

56 specialized enteral formula can be a useful adjunctive therapy by reducing lung inflammation and imp

57 In adolescents in particular, adjunctive therapies can be valuable, such as more inten

58 cking, pharmacologic and/or nonpharmacologic adjunctive therapy can be helpful in the treatment of th

59 al strategies may lead to the development of adjunctive therapies capable of improving outcomes.

60 s monotherapy in functional heartburn, or as adjunctive therapy combined with other therapeutic modal

61 pport routine nutritional supplementation or adjunctive therapies compared with standard care.

62 reduce morbidity and mortality, the role of adjunctive therapies continues to be explored.

63 SRP plus different adjunctive therapies could provide better information ab

64 Numerous and prolonged IVTs, used as adjunctive therapy, could improve the prognosis of treat

65 fforts focus on improving antiretroviral and adjunctive therapies, defining disease onset and progres

66 h structured program of diet and exercise as adjunctive therapy delivered in a cardiac rehabilitation

67 esults from SMC hyperplasia and suggest that adjunctive therapies designed to inhibit SMC proliferati

68 tion and suggests avenues for development of adjunctive therapy designed to augment host immunity.

69 Adjunctive therapy did not improve the likelihood of sur

70 -10-related mechanisms that could be used as adjunctive therapies during tuberculosis.

71 f such epileptogenesis remain unknown and no adjunctive therapy during cerebral malaria has been show

72 ycophenolic acid, exploration of alternative adjunctive therapies (eg, a mammalian target of rapamyci

73 When mechanical ventilation and adjunctive therapies fail, extracorporeal life support c

74 stry-sponsored phase 2/3 clinical trials for adjunctive therapies for antidepressant partial- and non

75 These findings might impact adjunctive therapies for cancer.

76 .Objectives: To describe contemporary use of adjunctive therapies for early PARDS as a framework for

77 ytic amyloidosis, which could be targeted as adjunctive therapies for HAND-associated Alzheimer-like

78 enzyme replacement for storage disorders and adjunctive therapies for metabolic disorders, as well as

79 tial attractive target for immune-modulating adjunctive therapies for neonatal sepsis.

80 ements and Main Results: We investigated six adjunctive therapies for PARDS: continuous neuromuscular

81 eview present pharmacological and mechanical adjunctive therapies for reperfusion and ask what is the

82 These findings suggest that alternative or adjunctive therapies for stent thrombosis are needed.

83 emains a strong need for non-antiarrhythmic, adjunctive therapies for the prevention of postoperative

84 e effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment.

85 et agents may prove beneficial in developing adjunctive therapies for use in combination with combine

86 iation is one of the most prevalent forms of adjunctive therapy for a variety of cancers, these resul

87 in for AMI were randomly assigned to receive adjunctive therapy for at least 3 days with either enoxa

88 agonists (antihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD).

89 terventions have the potential to be used as adjunctive therapy for behavioral weight management.

90 n, and calcineurin inhibitors may provide an adjunctive therapy for biliary pancreatitis.

91 Antidepressants may not be useful adjunctive therapy for bipolar depressed patients with h

92 initiated clinical trials by using rBPI21 as adjunctive therapy for children with severe meningococce

93 evaluating uric acid-lowering medications as adjunctive therapy for children with SM should be consid

94 f riluzole, a glutamatergic modulator, as an adjunctive therapy for children with treatment-resistant

95 t DON as a strong candidate for an effective adjunctive therapy for CM in African children.

96 thogenesis and nimodipine holds potential as adjunctive therapy for CM.

97 Leptin may be a potential adjunctive therapy for CMV viremia in undernourished tra

98 MK2 inhibition may be a valuable adjunctive therapy for control of pemphigus blistering.

99 ative properties, GLP-1 RAs may represent an adjunctive therapy for DFUs.

100 /UNICEF strategy for zinc supplementation as adjunctive therapy for diarrhea is poorly implemented.

101 reasoned that COP-1 could be developed as an adjunctive therapy for disease.

102 of studies is emerging that shows benefit of adjunctive therapy for DME.

103 ompared with unfractionated heparin (UFH) as adjunctive therapy for fibrinolysis in patients with ST-

104 rategy of using enoxaparin instead of UFH as adjunctive therapy for fibrinolysis in patients with STE

105 n when enoxaparin was used instead of UFH as adjunctive therapy for fibrinolysis in patients with STE

106 gG conjugates merit further study as a novel adjunctive therapy for gram-negative sepsis.

107 Nonstatin lipid-lowering therapy is adjunctive therapy for high-risk individuals on statins

108 rt consideration of this agent as a possible adjunctive therapy for histoplasmosis.

109 ase and as such warrants further study as an adjunctive therapy for human disease.

110 hen neurostimulation may become available as adjunctive therapy for medically intractable epilepsy.

111 ential clinical utility as either primary or adjunctive therapy for nephrotic syndrome or other disea

112 Furthermore, HO inhibitors may be useful adjunctive therapy for NTS infection in the context of h

113 mprovement in function and pain relief as an adjunctive therapy for osteoarthritis of the knee when c

114 neuropathy, generalized anxiety disorder and adjunctive therapy for partial seizures of epilepsy.

115 e been reported that support the efficacy of adjunctive therapy for patients with bipolar I depressio

116 esults suggest that estrogen may be a useful adjunctive therapy for patients with CHF.

117 X-2 inhibitors have been approved for use as adjunctive therapy for patients with familial polyposis.

118 ibition as a potential novel prophylactic or adjunctive therapy for patients with obesity-mediated AF

119 superior to unfractionated heparin (UFH) as adjunctive therapy for patients with ST-segment elevatio

120 This approach might be a useful adjunctive therapy for patients with uncontrolled hypert

121 asalazine could be an effective and specific adjunctive therapy for PcP, with the potential to accele

122 use, has the potential to be developed as an adjunctive therapy for PcP.

123 ntal health, and repeated PDT is a promising adjunctive therapy for periodontal treatment.

124 cogene c-fosDLCs could represent a promising adjunctive therapy for restoring iodide avidity within t

125 Adjunctive therapy for severe malaria has been seen as a

126 a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Stap

127 he possible development of brexanolone as an adjunctive therapy for SRSE requiring pharmacological co

128 ic therapies are beginning to be explored as adjunctive therapy for steroid-refractory ulcerative col

129 nal antibodies have progressively emerged as adjunctive therapy for steroid-resistant asthma, there r

130 in of Mycobacterium bovis, is widely used as adjunctive therapy for superficial bladder cancer.

131 attractive candidate for further study as an adjunctive therapy for the elimination of the latent HIV

132 te that inhibition of IKK may serve as novel adjunctive therapy for the prevention of graft rejection

133 ential importance of dietary phytosterols as adjunctive therapy for the treatment of hypercholesterol

134 aPDT is an effective adjunctive therapy for the treatment of periodontitis in

135 ermore, enhancing M2a polarization may be an adjunctive therapy for the treatment of Pneumocystis.

136 junal bypass liner (DJBL) may provide a safe adjunctive therapy for those with poorly controlled type

137 an indirect-acting antithrombin, heparin, as adjunctive therapy for thrombolysis in myocardial infarc

138 lin-1, and CD82 function may be an effective adjunctive therapy for treating epithelial cell malignan

139 ch indicate that rG-CSF may be beneficial as adjunctive therapy for treatment of serious bacterial an

140 mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset s

141 ntranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depress

142 Dexamethasone is recommended as adjunctive therapy for tuberculous meningitis (TBM).

143 Although corticosteroids are recommended as adjunctive therapy for tuberculous meningitis, the mecha

144 se), 0.4 mug/kg/hr (low dose), or placebo as adjunctive therapy for up to 5 days or resolution of wit

145 igned to enhance satiety may be an effective adjunctive therapy for weight loss; however, more resear

146 uggest that adaptive WMT may be an effective adjunctive therapy for WM deficits in HIV participants.

147 sy, quite a few of these studies showed that adjunctive therapy further reduced myocardial infarct si

148 ts, improvement of endoscopic technique, and adjunctive therapy, further reduction in recurrence rate

149 Several adjunctive therapies have undergone clinical trials in t

150 ntion by treatment assignment and the use of adjunctive therapies in 18 randomized clinical trials en

151 raged to confirm these findings and optimize adjunctive therapies in pediatric lupus.

152 n and corticosteroids are both commonly used adjunctive therapies in septic shock.

153 HDTs hold significant promise as adjunctive therapies in that they are less likely to eng

154 ventilator-induced lung injury and other new adjunctive therapies in the care of these patients.

155 n strategies as well as newer antithrombotic adjunctive therapies in the elderly with STEMI.

156 Adjunctive therapies in the form of intravitreal steroid

157 psychological interventions may be important adjunctive therapies in the medical management of RA.

158 We propose indapamide as a potential adjunctive therapy in aging-associated neurodegenerative

159 Alendronate is a useful adjunctive therapy in combination with enzyme replacemen

160 treatment of other atopic diseases and as an adjunctive therapy in conjunction with allergen-specific

161 aparin may potentially substitute for UFH as adjunctive therapy in fibrin-specific thrombolytic regim

162 ory cytokines have been used with success as adjunctive therapy in genetic disorders such as chronic

163 g regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients.

164 nimize tissue injury with high potential for adjunctive therapy in intra-abdominal sepsis.

165 eted against these proteins may be useful as adjunctive therapy in intubated patients with P. aerugin

166 s may open new possibilities for much needed adjunctive therapy in malaria.

167 emonstrate treatment shortening by verapamil adjunctive therapy in mice, and strongly support further

168 tion is warranted into the use of statins as adjunctive therapy in mucormycosis.

169 e data suggest that AAT may be beneficial as adjunctive therapy in patients undergoing islet transpla

170 le and effective antithrombotic treatment as adjunctive therapy in patients undergoing percutaneous c

171 ata support the role of rADAMTS13 as a novel adjunctive therapy in patients with iTTP.

172 ll-tolerated treatment that may be useful as adjunctive therapy in patients with MDR-TB who are other

173 hat clinicians use electrical stimulation as adjunctive therapy in patients with pressure ulcers to a

174 fit profile of SGLT2 inhibitors when used as adjunctive therapy in patients with type 1 diabetes.

175 Oxidation-resistant AAT could serve as adjunctive therapy in PR3-AAV.FUNDINGThis work was suppo

176 stress in CSF, suggesting a role of SSRIs as adjunctive therapy in PWH.

177 ith or without small-dose cyclosporine (CsA) adjunctive therapy in renal transplant recipients.

178 , there is no evidence for efficacy of ET as adjunctive therapy in severe malaria.

179 able on the use of ENOX compared with UFH as adjunctive therapy in STEMI patients treated with fibrin

180 Gabapentin has come into clinical use as adjunctive therapy in the treatment of epilepsy.

181 xidine (CHX) has been used extensively as an adjunctive therapy in the treatment of periodontal disea

182 a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underway.

183 ses, respectively, and thus may be useful as adjunctive therapy in those intracellular infections in

184 atements were developed regarding the use of adjunctive therapy in tubercular choroiditis.

185 uate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 autoimmune hepatitis, 37 pa

186 benefit was identified in 21 RCTs evaluating adjunctive therapies including electric current, ultraso

187 treatments are now often prescribed as late adjunctive therapy including pilocarpine, epinephrine co

188 tion, oral vancomycin reduces mortality, and adjunctive therapies (including IV metronidazole) and in

189 e last decade, clinical trials with numerous adjunctive therapies, including antiendotoxin antibodies

190 quired pneumonia treatment, but the roles of adjunctive therapies, including corticosteroids and immu

191 ory requirement for separate monotherapy and adjunctive-therapy indications in epilepsy is unnecessar

192 s consistently separated into monotherapy or adjunctive-therapy indications.

193 One proposed adjunctive therapy is sodium valproate (VPA), an anticon

194 Pending randomized evidence, if adjunctive therapy is to be used, ceftriaxone appears to

195 primary angioplasty and more frequent use of adjunctive therapies known to reduce mortality, and may

196 logy of progression also suggests that other adjunctive therapies may be possible.

197 Lamotrigine was used as adjunctive therapy (N = 60) or monotherapy (N = 15) in p

198 T cells are highly promising targets for CM adjunctive therapy, opening new avenues for the treatmen

199 f the United States population, with limited adjunctive therapy options.

200 therapy may represent a novel monotherapy or adjunctive therapy, or both, for CMV retinitis, especial

201 here is considerable interest in the role of adjunctive therapies, particularly ondansetron and probi

202 e in these patients, but the benefit of this adjunctive therapy remains controversial.

203 and provided new avenues for severe malaria adjunctive therapy research.

204 ltaneous advances in surgical techniques and adjunctive therapies, respiratory care, intensive care t

205 a to guide the clinician in choosing whether adjunctive therapy should be added to optimize response

206 sign features may also include incorporating adjunctive therapies such as antithrombotic or antiproli

207 Adjunctive therapies such as sodium glucose cotransporte

208 ombocytopenic purpura, but clinical data for adjunctive therapies, such as corticosteroids, antiplate

209 Promising old and new adjunctive therapies, such as pretreatment with beta-blo

210 However, adjunctive therapies sustaining inflammatory support ena

211 S disease, as well as the need for effective adjunctive therapies targeting monocytes and macrophages

212 the rationale to probe potential synergy of adjunctive therapy targeting CD4 and CD154 to overcome g

213 his procedure has been used predominantly as adjunctive therapy, targeting only the patient's clinica

214 rrently treated with antibiotics and various adjunctive therapies that are not very effective.

215 fective antimalarial therapy, development of adjunctive therapies that can attenuate CM progression c

216 Promising adjunctive therapies that target microvascular dysfuncti

217 Here, we demonstrate proof of concept for an adjunctive therapy that allows intravenous antibiotic tr

218 Such studies hold the promise of a novel adjunctive therapy that could make cancer chemotherapy m

219 ve disorders (HAND) underscores the need for adjunctive therapy that targets the neuropathological pr

220 ify molecular targets to devise iron-related adjunctive therapies to ameliorate HCC pathophysiology.

221 en HIV and its human host provides hope that adjunctive therapies to antiretroviral treatment can be

222 or and sensory trajectories and a variety of adjunctive therapies to augment the recovery of neurolog

223 tial usefulness of SIB-1508Y and levodopa as adjunctive therapies to improve at least some of the cog

224 Adjunctive therapies to lifestyle interventions, includi

225 cted mice, Opn may be a potential target for adjunctive therapies to reduce cardiac fibrosis in peopl

226 this process is an opportunity for targeted adjunctive therapies to reduce the morbidity and mortali

227 percutaneous coronary intervention (PCI), or adjunctive therapies to reperfusion by conducting an ele

228 y weight and glomerular growth may be useful adjunctive therapies to slow or prevent progression to E

229 uency (RF) electric-field hyperthermia as an adjunctive therapy to [60]fullerene nanoparticle-based d

230 s support the role of organic nitrates as an adjunctive therapy to ACE inhibitors in patients with ch

231 Ablation is usually adjunctive therapy to an ICD in these patients.

232 um tuberculosis growth, can be considered an adjunctive therapy to anti-tuberculosis treatment (ATT).

233 Corticosteroids are a potential adjunctive therapy to antibiotics.

234 Corticosteroids have been avoided as adjunctive therapy to antifungals in the treatment of ac

235 imesylate (LDX), a d-amphetamine prodrug, as adjunctive therapy to antipsychotics in adults with clin

236 ased therapy with interleukin-2 when used as adjunctive therapy to antiretroviral therapy may further

237 h varespladib 500 mg daily versus placebo as adjunctive therapy to atorvastatin 80 mg daily on biomar

238 f clinical chemoresistance, and implicate an adjunctive therapy to enhance chemotherapeutic response

239 Nitrite has significant potential as adjunctive therapy to enhance the efficacy of reperfusio

240 ical alternative to opioid therapy and/or an adjunctive therapy to facilitate opioid dose reduction w

241 tivity, and, in 2 different mouse models, as adjunctive therapy to first-line TB drugs.

242 ficacy and safety of aerosolized colistin as adjunctive therapy to i.v. antimicrobials or as monother

243 the concept that rapamycin can be used as an adjunctive therapy to improve efficacy of T(reg)-based i

244 SAND, suggesting that it may be an effective adjunctive therapy to increase survival and reduce organ

245 immunomodulators that are being evaluated as adjunctive therapy to interferon-based regimens.

246 ombination drug device Amikacin Inhale as an adjunctive therapy to intravenous standard-of-care antib

247 Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved wei

248 The use of pharmacological agents as adjunctive therapy to lifestyle modification is crucial,

249 should consider the use of synbiotics as an adjunctive therapy to prevent POCs among adult surgical

250 ction may represent a specific and effective adjunctive therapy to rapidly reverse the ongoing pathol

251 egulatory T cells (Treg) offer an attractive adjunctive therapy to reduce current reliance on lifelon

252 ging biomarker may be a promising target for adjunctive therapy to reduce the complications associate

253 imicrobial photodynamic therapy (aPDT) as an adjunctive therapy to scaling and root planing (SRP) for

254 reatments, PCSK9 remains the main target for adjunctive therapy to statins and ezetimibe through a va

255 proved survival and play a future role as an adjunctive therapy to surgical resection.

256 panders may offer yet another alternative or adjunctive therapy to the early rehabilitation of the co

257 Heparin and hirudin have an equal effect as adjunctive therapy to TPA and streptokinase in preventin

258 s inhibition could potentially be used as an adjunctive therapy to treat microbial keratitis and othe

259 ndividuals, catheter ablation may be used as adjunctive therapy to treat or prevent repetitive ICD th

260 death, and catheter ablation can be used as adjunctive therapy to treat or prevent repetitive ICD th

261 that can be used for testing the efficacy of adjunctive therapy to verteporfin PDT.

262 e world, income, and comorbidities influence adjunctive therapy use and are important variables to in

263 Rationale: Few data exist to guide early adjunctive therapy use in pediatric acute respiratory di

264 The potential role of adjunctive therapies used with HFOV (e.g., prone ventila

265 design, including lesion type, location, and adjunctive therapy used.

266 Adjunctive therapy was designed accordingly to deplete p

267 investigation, and empiric antimicrobial and adjunctive therapy were developed.

268 ries has identified potential candidates for adjunctive therapies, which may be combined with surgica

269 Finally, a discussion of adjunctive therapies will be included.

270 Patients were randomly assigned to adjunctive therapy with abciximab or placebo at the begi

271 etter assess clinical outcome are needed for adjunctive therapy with adenosine, K(ATP) channel opener

272 Unlike individual treatment regimens, adjunctive therapy with adenovirus-IL-4 and suboptimal d

273 to L-DOPA, supporting consideration of early adjunctive therapy with an A2A antagonist to reduce the

274 iteria for potential probiotic strains, test adjunctive therapy with antibiotics, and alternative dos

275 ovide support for clinical trials of MAbs as adjunctive therapy with antiretroviral therapy during ac

276 tial role for antifibrotic drug treatment as adjunctive therapy with ART to improve immune reconstitu

277 Standard adjunctive therapy with aspirin, ticlopidine, and hepari

278 us (Siro) vs. mycophenolate mofetil (MMF) as adjunctive therapy with calcineurin inhibitors (CI) in r

279 that investigate HIV-1-neutralizing MAbs as adjunctive therapy with cART during acute HIV-1 infectio

280 Adjunctive therapy with cyclosporine in this setting doe

281 Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST

282 arin compared with unfractionated heparin as adjunctive therapy with fibrinolysis.

283 The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent fe

284 Adjunctive therapy with granulocyte macrophage colony-st

285 er studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with

286 lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the tre

287 depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.

288 Adjunctive therapy with locally delivered antimicrobials

289 ly protect against drug-resistant strains in adjunctive therapy with meropenem, a standard-of-care an

290 arkers defined a subset of patients in which adjunctive therapy with omalizumab was associated with a

291 dentify subjects most likely to benefit from adjunctive therapy with omalizumab.

292 A double-blind, placebo-controlled study of adjunctive therapy with pentoxifylline (1800 mg/day) as

293 her used alone for prevention or possibly as adjunctive therapy with phlebotomy or chelation.

294 y was to evaluate the safety and efficacy of adjunctive therapy with poloxamer 188 in patients receiv

295 Adjunctive therapy with poloxamer 188 resulted in substa

296 Adjunctive therapy with rIFN- gamma 1b holds promise for

297 Adjunctive therapy with second-generation antidepressant

298 nhibitor use as a risk factor and the use of adjunctive therapy with specific probiotic, as it was ap

299 or mycophenolate mofetil (MMF) was tested as adjunctive therapy, with planned dose reductions of tacr

300 ents treated with topical corticosteroids as adjunctive therapy within 2 to 3 days of antibiotic ther